Acceleron Pharma expands pipeline
This article was originally published in Scrip
Executive Summary
Acceleron Pharma, a private US biotech firm, has expanded its development pipeline to seven internally discovered molecules with the addition of two novel preclinical development candidates, ACE-435 and ACE-661.